Vertex Pharmaceuticals Inc. (0QZU)
London Stock Exchange · UK · prices in USD · close of 27 Oct 2026
Key indicators
| Last close | USD 518.30 |
|---|---|
| 52-week range | 403.16 – 577.24 |
| Return, 1 month / 3 months | −1.4% / +7.8% |
| Return, 1 year / 3 years | +23.0% / +45.3% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 52 |
| Volatility (1 year) | 29.1% |
| Worst drawdown (1 year) | -15.8% |
| Average daily value traded | 0.91M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Vertex Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, that discovers and develops medicines for serious diseases. Its main business is treating cystic fibrosis with a family of oral drugs that target the underlying protein defects caused by the disease. It also develops and sells gene-editing therapies for blood disorders and has medicines for pain. Its customers are patients, physicians and healthcare systems, mainly in North America, Europe and other markets where its products are approved.
Vertex Pharmaceuticals Inc. trades under the code 0QZU on the London Stock Exchange in UK, with its price quoted in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Vertex Pharmaceuticals Inc. (0QZU) trades on the London Stock Exchange in UK. It last closed at USD 518.30 on 27 October 2026.
Its price-based Market X-Ray is 72 out of 100 (a strong price profile), ranking 435 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 23.0% and over the last three months it rose 7.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 75 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 8.2% | ||
| From 52-week high | -7.0% | ||
| Momentum | 77 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 7.8% | ||
| 6-month return | 21.0% | ||
| 12-month return, skipping the last month | 24.7% | ||
| Stability (higher is calmer) | 75 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 29.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -15.8% | ||
| Liquidity | 52 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.91M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +1.5% |
|---|---|
| 1 month | −1.4% |
| 3 months | +7.8% |
| 6 months | +21.0% |
| 1 year | +23.0% |
| 3 years | +45.3% |
| 5 years | +185.0% |
Signals
| 50-day / 200-day average | 523.22 / 478.85 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 20.00 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.